Statistics from Altmetric.com
‘I (Dimitrios Vassilopoulos), the corresponding author of this article which is contained within the original manuscript, which includes any diagrams photographs and any related or stand-alone film submitted (the ‘Contribution’), has the right to grant on behalf of all authors, and does grant on behalf of all authors, a licence to the BMJ Publishing Group Ltd and its licensees, to permit this contribution (if accepted) to be published in any BMJ Group products, and to exploit all subsidiary rights, as per our licence set out at (http://group.bmj.com/products/journals/instructions-for-authors/co_owned_licence.pdf).
Patients with rheumatic diseases and chronic, or less frequently, resolved hepatitis B virus (HBV) infection, can develop viral reactivation during antitumor necrosis factor therapy.1–3 Treatment with chemotherapeutic regimens that includes rituximab (RTX) without prophylactic antiviral therapy, has been linked to HBV reactivation in lymphoma patients with chronic (27%–80%), or resolved (3%–25%) HBV infection.1 ,4 Since there are no data available for rheumatic patients, we studied the safety of …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.